Quoin Pharmaceuticals, Ltd. — Capital/Financing Update 2016

Jul 26, 2016

CORRESP 1 filename1.htm

July 26, 2016

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Re: CELLECT BIOTECHNOLOGY LTD.

Registration Statement on Form F-1 (Registration No. 333-212432) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“ Wainwright ”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Cellect Biotechnology Ltd. that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on July 28, 2016, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC
By:	/s/ Mark W. Viklund
	Name: Mark W. Viklund
	Title: Chief Executive Officer

Field: Page; Sequence: 1; Options: Last

Field: /Page